当前位置： SCI文献检索 > JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS期刊下所有文献 > GPs' views on computerized drug interaction alerts: questionnaire survey.

GPs' views on computerized drug interaction alerts: questionnaire survey.

Abstract：

BACKGROUND:There is evidence that patients are being prescribed potentially hazardous drug-drug combinations in general practice despite the use of computerized drug interaction alert systems. One reason for this may be that general practitioners (GPs) are overriding these alerts without properly checking them. AIMS:(i) To assess GPs views on the relevance of information provided by alert systems; (ii) To determine the proportion of GPs that admit to frequently overriding interaction alerts without properly checking them and (iii) To explore factors that might be associated with a tendency to override alerts. METHODS:Questionnaire survey of GPs in four primary care trusts in the Nottingham area of the UK. RESULTS:The response rate was 70% (236 of 336) and detailed analysis was conducted on the 220 respondents who had drug interaction alert systems on their practice computers. Of these, 22% (49 of 220) admitted to frequently or very frequently overriding drug interaction alerts without properly checking them. Potential reasons for overriding alerts included the perception that the alerts were frequently irrelevant. Nevertheless 90% (198 of 219) agreed that it should be more difficult to override alerts for potentially lethal drug combinations. Logistic regression analysis showed that users of the EMIS (Egton Medical Information Systems) computer system were much less likely to admit to overriding alerts without properly checking them than users of other computer systems. CONCLUSION:A minority of GPs admit to frequently overriding their drug interaction alert systems without properly checking them. The type of computer system used by GPs may make it more or less likely that they override alerts.

journal_name

J Clin Pharm Ther

journal_title

Journal of clinical pharmacy and therapeutics

authors

Magnus D,Rodgers S,Avery AJ

doi

10.1046/j.1365-2710.2002.00434.x

subject

Has Abstract

pub_date

2002-10-01 00:00:00

pages

377-82

issue

5

eissn

0269-4727

issn

1365-2710

pii

434

journal_volume

27

pub_type

杂志文章

相关文献

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS文献大全
  • Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Alzheimer's disease (AD) is the most common cause of dementia among the elderly. The exact cause of the disease is not clearly known, and no existing therapies are able to prevent disease progression. Identification of the possible "impaired brain insulin signalling in AD" enriched the scope...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/jcpt.12808

    authors： Jojo GM,Kuppusamy G

    更新日期：2019-06-01 00:00:00

  • Drug-induced parotitis.

    abstract：:Drug-induced parotitis is a relatively uncommon adverse drug reaction. Most of the data on drug-induced parotitis consist of isolated case reports with few attempts at rechallenge to confirm the aetiology. Phenylbutazone and oxyphenbutazone have a significant number of reports suggesting that these drugs may be implic...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2710.1993.tb00584.x

    authors： Thompson DF

    更新日期：1993-08-01 00:00:00

  • Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia.

    abstract：OBJECTIVE:There is a growing interest in investigating the role of glutamate receptors in the pathophysiology of schizophrenia. Indeed, the hyperdopaminergic theory of schizophrenia can explain only the positive symptoms of schizophrenia, whereas the glutamate hypothesis may provide a more comprehensive view of the ill...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2710.1999.00238.x

    authors： Noorbala AA,Akhondzadeh S,Davari-Ashtiani R,Amini-Nooshabadi H

    更新日期：1999-10-01 00:00:00

  • A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Niacin commonly causes cutaneous flushing, which is partially alleviated by laropiprant, a selective antagonist of prostaglandin D2 at the DP1 receptor. Here we report an unusually high incidence of exanthematous eruption associated with the use of the extended-release (ER) niacin/laropipran...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/jcpt.12096

    authors： Yang YL,Hu M,Chang M,Tomlinson B

    更新日期：2013-12-01 00:00:00

  • Comparison of two databases to detect potential drug-drug interactions between prescriptions of HIV/AIDS patients in critical care.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Adverse drug events (ADE), common and underestimated in ICU patients, have direct consequences on length of stay, mortality and hospital costs. Critically ill patients with HIV/AIDS are at a high risk of ADE because of their need for multiple drug therapies. ADE can be prevented, especially ...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/jcpt.12222

    authors： Ramos GV,Guaraldo L,Japiassú AM,Bozza FA

    更新日期：2015-02-01 00:00:00

  • Pharmacokinetics of intravenous midazolam during epidural anaesthesia.

    abstract：:Midazolam concentration curves versus time were analysed in 10 otherwise healthy patients (ASA I-II) with inferior limb pathologies. The benzodiazepine was used as an adjuvant agent to epidural anaesthesia in view of its lower residual effect compared with other intravenous benzodiazepines. Midazolam pharmacokinetics...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2710.1991.tb00306.x

    authors： Sánchez-Alcaraz A,Sangrador G,Laguarda M,Quintana B

    更新日期：1991-06-01 00:00:00

  • Does levodopa improve swallowing dysfunction in Parkinson's disease patients?

    abstract：OBJECTIVE:To assess the influence of levodopa on swallowing dysfunction in Parkinson's disease patients. METHODS:A systematic review of the literature and a meta-analysis were performed. All studies referring to levodopa and swallowing dysfunction that provided direct data or data that could be transformed into mean +...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1111/j.1365-2710.2009.01031.x

    authors： Menezes C,Melo A

    更新日期：2009-12-01 00:00:00

  • A randomized controlled trial of a new ovule formulation of ornidazole for the treatment of bacterial vaginosis.

    abstract：OBJECTIVE:To compare the efficacy of 500 mg ornidazole vaginal ovules (VO) and vaginal tablets (VT) in the treatment of bacterial vaginosis. METHOD:Patients were allocated at random to one group of 50 subjects to be treated with a VO (500 mg) prepared in our laboratory and to a second group of 50 subjects to be treate...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2710.2003.00472.x

    authors： Baloğlu E,Ozyazici M,Baloğlu A,Ova L

    更新日期：2003-04-01 00:00:00

  • Management of acute coronary syndrome in a tertiary care general medical unit in Sri Lanka: how closely do we follow the guidelines?

    abstract：BACKGROUND AND OBJECTIVES:Acute coronary syndrome (ACS) is a leading cause of death. Correct implementation of evidence-based guidelines should improve outcome. We conducted this study to determine to what extent management of ACS in a tertiary care medical ward in Sri Lanka adhered to current guidelines. STUDY METHOD...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2710.2009.01115.x

    authors： Rajapakse S,Rodrigo PC,Selvachandran J

    更新日期：2010-08-01 00:00:00

  • Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy.

    abstract：WHAT IS KNOWN AND OBJECTIVE:One-third of patients with epilepsy are resistant to anti-epileptic drugs (AEDs). Drug-resistant epilepsy is believed to be multifactorial involving both genetic and non-genetic factors. Genetic variations in the ABCB1 gene encoding the drug efflux transporter, p-glycoprotein (p-gp), may inf...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/jcpt.12263

    authors： Keangpraphun T,Towanabut S,Chinvarun Y,Kijsanayotin P

    更新日期：2015-06-01 00:00:00

  • Re-elevation of serum amlodipine level after lipid emulsion therapy in an overdose case.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Amlodipine overdose is common; however, the dose and timing of intravenous lipid emulsion (ILE) therapy as a management strategy remain debatable. CASE DESCRIPTION:A 73-year-old man received a single bolus (1.5 mL/kg) of ILE therapy following massive ingestion of multiple drugs, including a...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type：

    doi：10.1111/jcpt.13018

    authors： Ando M,Nakasako S,Ariyoshi K,Yamaguchi M,Sakizono K,Minowa K,Fukushima S,Sugioka N,Hashida T

    更新日期：2019-12-01 00:00:00

  • Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.

    abstract：BACKGROUND AND OBJECTIVE:Enteric-coated, delayed-release divalproex sodium requires multiple daily administrations and high adherence rate to prevent breakthrough seizures and control adverse effects. We evaluated the effect of missing one or two doses of divalproex for up to 24 h, followed by replacement and resumptio...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2710.2006.00739.x

    authors： Dutta S,Reed RC

    更新日期：2006-08-01 00:00:00

  • Appropriateness of antiviral prescribing for influenza in primary care: a retrospective analysis.

    abstract：BACKGROUND AND OBJECTIVE:Antiviral medications cost-effectively reduce influenza-related morbidity and potentially mortality. We sought to assess the appropriateness of antiviral prescribing for influenza. METHOD:We performed a retrospective analysis of visits by adults to primary care clinics during influenza seasons...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2710.2006.00731.x

    authors： Linder JA,Chan JC,Bates DW

    更新日期：2006-06-01 00:00:00

  • Socio-demographic differences in adherence to evidence-based drug therapy after hospital discharge from acute myocardial infarction: a population-based cohort study in Rome, Italy.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Adherence to evidence-based drug therapy after acute myocardial infarction has increased over the last decades, but is still unsatisfactory. Our objectives are to set out to analyse patterns of evidence-based drug therapy after acute myocardial infarction (AMI), and evaluating socio-demograp...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2710.2010.01242.x

    authors： Kirchmayer U,Agabiti N,Belleudi V,Davoli M,Fusco D,Stafoggia M,Arcà M,Barone AP,Perucci CA

    更新日期：2012-02-01 00:00:00

  • Survival without peripheral neuropathy after massive acute arsenic poisoning: Treated by 2,3-dimercaptopropane-1-sulphonate.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Massive acute arsenic poisoning is rare yet potentially life-threatening. 2,3-dimercaptopropane-1-sulphonate (DMPS) appears to have the appropriate chelating property. However, clinical experience on the use of DMPS in massive arsenic poisoning is limited. CASE DESCRIPTION:A 37-year-old wom...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type：

    doi：10.1111/jcpt.12538

    authors： Lu PH,Tseng JC,Chen CK,Chen CH

    更新日期：2017-08-01 00:00:00

  • Echinacea intake induces an immune response through altered expression of leucocyte hsp70, increased white cell counts and improved erythrocyte antioxidant defences.

    abstract：OBJECTIVE:To study the effect of Echinacea tablets on the expression of leucocyte heat shock protein 70 (hsp70), erythrocyte haemolysis, plasma antioxidant status, serum chemistry, haematological values and plasma alkylamide concentrations. METHOD:Eleven healthy individuals (26-61 years of age) were evaluated at basel...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1111/j.1365-2710.2005.00658.x

    authors： Agnew LL,Guffogg SP,Matthias A,Lehmann RP,Bone KM,Watson K

    更新日期：2005-08-01 00:00:00

  • How high should total pain-relief score be to obviate the need for analgesic remedication in acute pain? Estimation using signal detection theory and individual-patient meta-analysis.

    abstract：BACKGROUND:A pain relief score 50% of the maximum is often used as a clinically meaningful outcome in meta-analyses of analgesic trials. This arbitrary value requires validation. OBJECTIVE:To determine the optimum pain relief score for predicting pain relief sufficient to obviate the need for analgesic remedication in...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1111/j.1365-2710.2006.00719.x

    authors： Li Wan Po A,Petersen B

    更新日期：2006-04-01 00:00:00

  • Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Rituximab, an anti-CD20 monoclonal antibody, is widely used with good response for the treatment of B-cell lymphoma and various refractory autoimmune diseases. Although rituximab is effective, rare but serious pulmonary adverse reactions have been reported. We report on a case of rituximab-i...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/jcpt.12052

    authors： Wu Y,Jia Y,Xu J,Shuai X,Wu Y

    更新日期：2013-06-01 00:00:00

  • Chemoradiation combined with regional hyperthermia for advanced oesophageal cancer: a systematic review and meta-analysis.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Hyperthermia is an effective treatment modality that augments the anticancer effects of radiotherapy and chemotherapy. Hyperthermia-chemo-radiotherapy (HCRT) is a combination therapy that can strengthen anticancer effects through a synergistic interaction between heat, chemotherapy and radia...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章,meta分析,评审

    doi：10.1111/jcpt.12498

    authors： Hu Y,Li Z,Mi DH,Cao N,Zu SW,Wen ZZ,Yu XL,Qu Y

    更新日期：2017-04-01 00:00:00

  • Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: a case report.

    abstract：:New treatments for relapse of acute myeloid leukaemia (AML), include gemtuzumab ozogamicin (GO), an anti-CD33 monoclonal antibody. We describe a second case of GO-induced sinusoidal obstructive syndrome (SOS) effectively treated with defibrotide (DF). No stem-cell transplantation was involved. On day 23 after the firs...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2710.2006.00742.x

    authors： Lannoy D,Decaudin B,Grozieux de Laguérenne A,Barrier F,Pignon JM,Wetterwald M,Odou P

    更新日期：2006-08-01 00:00:00

  • QTc prolongation during antiviral therapy in two COVID-19 patients.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Acquired long QT syndrome secondary to drug-induced QT prolongation and torsades de pointes has been reported for antiviral drugs. However, no studies have reported an association between corrected QT (QTc) prolongation and antiviral therapy in patients with novel coronavirus disease (COVID-...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type：

    doi：10.1111/jcpt.13183

    authors： Zhu S,Wang J,Wang Y,Chu J,Liu Y,Chen X,Chen X

    更新日期：2020-10-01 00:00:00

  • Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Psoriatic arthritis is an autoimmune disease characterized by chronic inflammation of the skin and joints. Anti-TNF drugs reduce the severity of the disease in the long term. This study compares the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in patients with psor...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章,meta分析,评审

    doi：10.1111/jcpt.12045

    authors： Fénix-Caballero S,Alegre-del Rey EJ,Castaño-Lara R,Puigventós-Latorre F,Borrero-Rubio JM,López-Vallejo JF

    更新日期：2013-08-01 00:00:00

  • Diphenhydramine dependence through deep intramuscular injection resulting in myonecrosis and prolonged QT interval.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Diphenhydramine (DPH) is a first-generation antihistamine, which is useful in treating allergic reaction, and is usually considered innocuous. We describe a retired nurse with history of depression, who began to develop drug-seeking behaviour after her first receiving of an intramuscular (IM...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/jcpt.12142

    authors： Chen TY,Yeh YW,Kuo SC,Chen CY,Lin TP,Chang CC

    更新日期：2014-06-01 00:00:00

  • Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Clinically validated pharmacogenomic information useful for patient selection and/or dose adjustment is included in drug labels. However, the label information may differ among countries. This commentary summarizes the pharmacogenomic information on drug labels in different countries. COMME...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/jcpt.12691

    authors： Imatoh T,Sai K,Saito Y

    更新日期：2018-08-01 00:00:00

  • Patients' intention to consume prescribed and non-prescribed medicines: A study based on the theory of planned behaviour in selected European countries.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Polypharmacy has a significant impact on patients' health with overall expenditure on over-the-counter (OTC) medicines representing a substantial burden in terms of cost of treatment. The aim of this study, which was conducted within the framework of a European Project funded by the European...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/jcpt.12601

    authors： Kamekis A,Bertsias A,Moschandreas J,Petelos E,Papadakaki M,Tsiantou V,Saridaki A,Symvoulakis EK,Souliotis K,Papadakis N,Faresjö T,Faresjö A,Martinez L,Agius D,Uncu Y,Sengezer T,Samoutis G,Vlcek J,Abasaeed A,Merkouri

    更新日期：2018-02-01 00:00:00

  • Computerized pharmaceutical intervention to reduce reconciliation errors at hospital discharge in Spain: an interrupted time-series study.

    abstract：WHAT IS KNOWN AND OBJECTIVE:It is well known that medication reconciliation at discharge is a key strategy to ensure proper drug prescription and the effectiveness and safety of any treatment. Different types of interventions to reduce reconciliation errors at discharge have been tested, many of which are based on the ...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/jcpt.12365

    authors： García-Molina Sáez C,Urbieta Sanz E,Madrigal de Torres M,Vicente Vera T,Pérez Cárceles MD

    更新日期：2016-04-01 00:00:00

  • The effect of high dose of N-acetylcysteine in lupus nephritis: a case report and literature review.

    abstract：:An imbalance of oxidative-antioxidant defence mechanism has been proposed in systemic lupus erythematosus patients. Co-administration of N-acetylcysteine (NAC) which has a strong antioxidant activity may produce a satisfactory therapeutic outcome when added to standard therapy. We report a case of a 46-year-old lupus ...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2710.2009.01108.x

    authors： Tewthanom K,Janwitayanujit S,Totemchockcyakarn K,Panomvana Na Ayudhya D

    更新日期：2010-08-01 00:00:00

  • Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Pregabalin is used for neuropathic and postherpetic pain and generalized anxiety. The aim of this study was to obtain the onset profiles of adverse events (AE) related to falls (AEFs) such as "somnolence," "dizziness," "loss of consciousness" and "fall" onset and several clinical factor comb...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/jcpt.12790

    authors： Mukai R,Hasegawa S,Umetsu R,Nakao S,Shimada K,Uranishi H,Masuta M,Suzuki H,Nishibata Y,Nakamura M

    更新日期：2019-04-01 00:00:00

  • Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Limited data are available on co-administration of acenocoumarol with direct-acting antiviral agents for chronic hepatitis C virus infection. CASE SUMMARY:We report a case of a patient who required a significant increase in acenocoumarol weekly dose probably due to an interaction with ombit...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type：

    doi：10.1111/jcpt.12403

    authors： de Lorenzo-Pinto A,Giménez-Manzorro Á,Rodríguez-González CG,Ahumada-Jiménez A,Herranz-Alonso A,Marzal-Alfaro MB,Sanjurjo-Sáez M

    更新日期：2016-08-01 00:00:00

  • Colchicine toxicity precipitated by interaction with sunitinib.

    abstract：WHAT IS KNOWN AND OBJECTIVE:Colchicine is an anti-inflammatory agent used primarily in treatment of gout and familial Mediterranean fever. Toxicity is uncommon, and depends on dose, hepatic or renal impairment, co-administration with P-glycoprotein or CYP3A4 inhibitors and route of administration. In patients taking p-...

    journal_title：Journal of clinical pharmacy and therapeutics

    pub_type： 杂志文章

    doi：10.1111/jcpt.12047

    authors： Abodunde OA,LevakaVeera RR,Desai R,Nweke N,Berrou M

    更新日期：2013-06-01 00:00:00